Form 4: Axsome Director Exercises Stock Options, Boosts Stake

Axsome Therapeutics Director Mark Coleman exercised 12,485 stock options at $4.95 per share, increasing his direct beneficial ownership.

Summary

• Mark Coleman, a Director of Axsome Therapeutics, Inc. (AXSM), exercised 12,485 stock options.
• The exercise price for these options was $4.95 per share.
• The transaction occurred on February 20, 2026.
• Following the exercise, Mr. Coleman directly holds 65,890 shares of Common Stock.
• He also indirectly beneficially owns 403,856 shares through an entity where he has voting and dispositive power.
• The exercised options were part of a grant exercisable since March 15, 2018, and were set to expire on March 15, 2027.
• After this transaction, Mr. Coleman retains 13,971 unexercised stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director is increasing their direct equity stake, which generally aligns their interests with shareholders. It's a routine transaction but holding the shares adds a positive nuance.

Positives

• A director increasing their direct shareholding through option exercise can signal confidence in the company's future prospects.
• The exercise of options prior to expiration indicates a strategic decision to convert potential value into actual equity, rather than letting them expire or immediately selling.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises, are common occurrences in publicly traded companies. While this specific transaction by a director of Axsome Therapeutics is routine, it can be interpreted by the market as a sign of continued alignment between management and shareholder interests, particularly when the underlying shares are held rather than immediately sold.

Related Party Transactions

• The exercise of stock options by a director is inherently a related party transaction, as it involves a company insider acquiring equity from the company under pre-existing compensation agreements.

Stakeholder Impact

• Shareholders: The director's increased direct ownership could be seen as a positive signal of confidence in the company's future.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised stock options and retained the shares. While it signals confidence, it does not provide new fundamental information about Axsome Therapeutics' operational performance or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals rather than this specific insider transaction.

Keywords

Axsome Therapeutics, AXSM, Mark Coleman, Director, Stock Options, Insider Trading, Beneficial Ownership, SEC Form 4, Equity Exercise